Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Acne vulgaris is a self-limiting disorder that affects primarily teenagers and young adults. In adolescence, sebaceous glands increase sebum release after puberty. Small cysts called comedones form in hair follicles due to blockage of the pore due to retention of sebum and keratinous material. Bacterial activity within the comedones releases free fatty acids from sebum, causing inflammation within the cyst. This results in rupture of the cyst wall and subsequent inflammatory reaction due to extrusion of oily and keratinous debris from the cyst. The goal of therapy is elimination of comedones. This is achieved by decreasing sebaceous gland activity, bacterial population, and inflammation with antibiotics, benzoyl peroxide, retinoids or their combinations.

Total program savings for the PDL classes will be regularly reviewed.
**Program-Specific Information:**

<table>
<thead>
<tr>
<th>Preferred Agents</th>
<th>Non-Preferred Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Differin® 0.1% Crm/Lot</td>
<td>• Adapalene 0.1%</td>
</tr>
<tr>
<td>• Differin® 0.3% Gel Pump Rx</td>
<td>• Adapalene 0.3%</td>
</tr>
<tr>
<td>• Retin-A® Crm/Gel</td>
<td>• Adapalene/Benzoyl Peroxide</td>
</tr>
<tr>
<td>• Tazorac® Gel</td>
<td>• Aklief®</td>
</tr>
<tr>
<td>• Differin® 0.1% Gel OTC/Rx</td>
<td>• Altreno™</td>
</tr>
<tr>
<td>• Differin® 0.3% Gel Rx</td>
<td>• Arazlo™</td>
</tr>
<tr>
<td>• Epiduo®</td>
<td>• Atralin®</td>
</tr>
<tr>
<td>• Epiduo® Forte</td>
<td>• Clindamycin/Tretinoin</td>
</tr>
<tr>
<td>• Fabior®</td>
<td>• Differin® 0.1% Gel OTC/Rx</td>
</tr>
<tr>
<td>• Retin-A® Micro® Gel/Pump</td>
<td>• Differin® 0.3% Gel Rx</td>
</tr>
<tr>
<td>• Tazarotene</td>
<td>• Epiduo®</td>
</tr>
<tr>
<td>• Tazarac® Crm</td>
<td>• Fabior®</td>
</tr>
<tr>
<td>• Tretinoin Crm/Gel</td>
<td>• Retin-A® Micro® Gel/Pump</td>
</tr>
<tr>
<td>• Tretinoin Micro Gel</td>
<td>• Tazarotene</td>
</tr>
<tr>
<td>• Tretin-X™</td>
<td>• Tazorac® Gel</td>
</tr>
<tr>
<td>• Veltin®</td>
<td>• Tretinoid Crm/Gel</td>
</tr>
<tr>
<td>• Ziana®</td>
<td>• Tretin-X™</td>
</tr>
</tbody>
</table>

- **Agents that are for cosmetic use only and are not covered:**
  - Refissa™
  - Renova®

**Type of Criteria:**
- [ ] Increased risk of ADE
- [x] Preferred Drug List
- [x] Appropriate Indications
- [ ] Clinical Edit

**Data Sources:**
- [ ] Only Administrative Databases
- [x] Databases + Prescriber-Supplied

**Setting & Population**
- Drug class for review: Retinoids, Topical
- Age range: All appropriate MO HealthNet participants

**Approval Criteria**

- For tazarotene: documented diagnosis of psoriasis OR
- Documented diagnosis of acne vulgaris or drug induced acne in the past two years: adequate therapeutic trial of benzoyl peroxide OR
- Documentation of appropriate diagnosis AND
- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents
  - Documented trial period for preferred agents OR
  - Documented ADE/ADR to preferred agents

**Denial Criteria**
- Therapy will be denied if no approval criteria are met
- Lack of adequate trial on required preferred agents

---

*SmartPA PDL Proposal Form*

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.
Required Documentation

Laboratory Results: [ ]  Progress Notes: [ ]
MedWatch Form: [ ]  Other: [ ]

Disposition of Edit

Denial: Exception Code “0160” (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

4. USPDI, Micromedex; 2020.
5. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.